marking a pivotal milestone in our quest to expand clinical research in this field. By working hand in hand, we are confident that our collaboration will enable optimal cancer care, further potential clinical indications for carbon ion therapy, and shape the future of healthcare in the region and beyond.”
Shigeo Koyasu, President of QST said: “It is wonderful to start research cooperation with M42. This MOC will promote widespread use of carbon ion radiotherapy and help build a healthy and long-lived society with zero cancer deaths.”
QST was established in 2016 and is striving to establish world-leading research and development platforms, explore new fields, and serve as a center for radiation protection and radiation emergency medicine.
